Sumitomo, Otsuka’s Schizophrenia Candidate Fails Phase III Trials

Sumitomo Pharma and Otsuka Pharmaceutical announced Monday that two Phase III studies of ulotaront failed to meet primary endpoints for acutely psychotic adults living with schizophrenia.